piAS3: A Potential Drug Target and Biomarker for Inflammatory Diseases

Target Name: PIAS3

NCBI ID: G10401

PIAS3

piAS3: A Potential Drug Target and Biomarker for Inflammatory Diseases

PIAS3: A Potential Drug Target and Biomarker forFLJ14651Inflammatory diseases such as rheumatoid arthritis, fibrosis, and cancer have a significant impact on public health, leading to significant morbidity and mortality worldwide. The immune system, which is crucial in fighting off these diseases, is also affected by them. Many diseases result from the activation and proliferation of immune cells that malfunction or become uncontrolled. One of the key factors in this process is the production of pro-inflammatory cytokines, which contribute to the inflammation that follows. piAS3, a protein that is expressed in various tissues and cells, has been identified as a potential drug target and biomarker for inflammatory diseases. In this article, we will discuss the biology of piAS3 and its potential in the treatment of inflammatory diseases.

Overview ofpiAS3

piAS3, which stands for phosphatidyltransferase 3, is a protein that is expressed in various tissues and cells. It is a member of the PIAS family of enzymes, which are involved in the transfer of phosphate groups to other proteins. piAS3 is involved in the production of pro-inflammatory cytokines, including TNF-?±, IL-1??, and IL-6. These cytokines play a crucial role in the regulation of immune responses and have been implicated in the development and progression of many inflammatory diseases.

Inflammation is a critical response of the immune system to harmful stimuli, such as bacteria, viruses, and tissue injury. When the immune system is activated, it produces cytokines that help to recruit and activate immune cells, including T cells, B cells, and Macrophages. These cytokines also stimulate the production of other pro-inflammatory cytokines, which contribute to the production of pro-inflammatory mediators, such as chemokines and eicosanoids.

However, if the immune system becomes uncontrolled or dysregulated, it can lead to the development of inflammatory diseases, including rheumatoid arthritis, fibrosis, and cancer. These diseases are characterized by the production of excessive amounts of pro-inflammatory cytokines, which can cause a persistent inflammatory response that can lead to damage to tissues and organs.

PiAS3 as a drug target

The potential of piAS3 as a drug target is based on its involvement in the production of pro-inflammatory cytokines. Many treatments for inflammatory diseases are designed to reduce the production of these cytokines and alleviate their symptoms. By targeting piAS3, researchers and clinicians may be able to develop new and more effective treatments for inflammatory diseases.

One approach to targeting piAS3 is to use small molecules that inhibit its activity. These small molecules can be found in natural compounds, such as those derived from plants or animals, or in synthetic compounds that are designed to selectively bind to piAS3. Some studies have shown that inhibitors of piAS3 have the potential to alleviate symptoms of inflammatory diseases, including rheumatoid arthritis and cancer.

In addition to its potential as a drug target, piAS3 has also been identified as a potential biomarker for inflammatory diseases. The production of pro-inflammatory cytokines is a key feature of inflammatory diseases, and piAS3 is involved in this process. Therefore, its levels may be a useful indicator of the severity and activity of inflammatory diseases.

PiAS3 as a biomarker

The production of pro-inflammatory cytokines is a key feature of inflammatory diseases, and piAS3 is involved in this process. Therefore, its levels may be a useful indicator of the severity and activity of inflammatory diseases. Several studies have shown that piAS3 levels can be Elevated in individuals with inflammatory diseases, such as rheumatoid arthritis and cancer.

In addition to its potential as a drug target, piAS3 has also been identified as a potential biomarker for inflammatory diseases. The production of pro-inflammatory cytokines is a key feature of inflammatory diseases, and piAS3 is involved in this process. Therefore, its levels may be a useful indicator of the severity and activity of inflammatory diseases.

Conclusion

In conclusion, piAS3 is a protein that is involved in the production of pro-inflammatory cytokines. Its levels can be elevated in individuals with inflammatory diseases, making it a potential biomarker for these conditions. In addition, piAS3 has also been identified as a potential drug target for the treatment of inflammatory diseases. Further research is needed to fully understand its role in the development and progression of inflammatory diseases.

Protein Name: Protein Inhibitor Of Activated STAT 3

Functions: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway and the steroid hormone signaling pathway. Involved in regulating STAT3 signaling via inhibiting STAT3 DNA-binding and suppressing cell growth. Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation (PubMed:21965678, PubMed:9388184). Sumoylates CCAR2 which promotes its interaction with SIRT1 (PubMed:25406032). Diminishes the sumoylation of ZFHX3 by preventing the colocalization of ZFHX3 with SUMO1 in the nucleus (PubMed:24651376)

The "PIAS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIAS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets